Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

  1. Guan, Wei-jie
  2. Liang, Wen-hua
  3. Zhao, Yi
  4. Liang, Heng-rui
  5. Chen, Zi-sheng
  6. Li, Yi-min
  7. Liu, Xiao-qing
  8. Chen, Ru-chong
  9. Tang, Chun-li
  10. Wang, Tao
  11. Ou, Chun-quan
  12. Li, Li
  13. Chen, Ping-yan
  14. Sang, Ling
  15. Wang, Wei
  16. Li, Jian-fu
  17. Li, Cai-chen
  18. Ou, Li-min
  19. Cheng, Bo
  20. Xiong, Shan
  21. Ni, Zheng-yi
  22. Xiang, Jie
  23. Hu, Yu
  24. Liu, Lei
  25. Shan, Hong
  26. Lei, Chun-liang
  27. Peng, Yi-xiang
  28. Wei, Li
  29. Liu, Yong
  30. Hu, Ya-hua
  31. Peng, Peng
  32. Wang, Jian-ming
  33. Liu, Ji-yang
  34. Chen, Zhong
  35. Li, Gang
  36. Zheng, Zhi-jian
  37. Qiu, Shao-qin
  38. Luo, Jie
  39. Ye, Chang-jiang
  40. Zhu, Shao-yong
  41. Cheng, Lin-ling
  42. Ye, Feng
  43. Li, Shi-yue
  44. Zheng, Jin-ping
  45. Zhang, Nuo-fu
  46. Zhong, Nan-shan
  47. He, Jian-xing

Download
2000547.full.pdf 417,89KB
WeightNameValue
1000 Titel
  • Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis
1000 Autor/in
  1. Guan, Wei-jie |
  2. Liang, Wen-hua |
  3. Zhao, Yi |
  4. Liang, Heng-rui |
  5. Chen, Zi-sheng |
  6. Li, Yi-min |
  7. Liu, Xiao-qing |
  8. Chen, Ru-chong |
  9. Tang, Chun-li |
  10. Wang, Tao |
  11. Ou, Chun-quan |
  12. Li, Li |
  13. Chen, Ping-yan |
  14. Sang, Ling |
  15. Wang, Wei |
  16. Li, Jian-fu |
  17. Li, Cai-chen |
  18. Ou, Li-min |
  19. Cheng, Bo |
  20. Xiong, Shan |
  21. Ni, Zheng-yi |
  22. Xiang, Jie |
  23. Hu, Yu |
  24. Liu, Lei |
  25. Shan, Hong |
  26. Lei, Chun-liang |
  27. Peng, Yi-xiang |
  28. Wei, Li |
  29. Liu, Yong |
  30. Hu, Ya-hua |
  31. Peng, Peng |
  32. Wang, Jian-ming |
  33. Liu, Ji-yang |
  34. Chen, Zhong |
  35. Li, Gang |
  36. Zheng, Zhi-jian |
  37. Qiu, Shao-qin |
  38. Luo, Jie |
  39. Ye, Chang-jiang |
  40. Zhu, Shao-yong |
  41. Cheng, Lin-ling |
  42. Ye, Feng |
  43. Li, Shi-yue |
  44. Zheng, Jin-ping |
  45. Zhang, Nuo-fu |
  46. Zhong, Nan-shan |
  47. He, Jian-xing |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-05-14
1000 Erschienen in
1000 Quellenangabe
  • 55:2000547
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1183/13993003.00547-2020 |
1000 Ergänzendes Material
  • https://erj.ersjournals.com/content/55/5/2000547#sec-18 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide. OBJECTIVE To evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status. METHODS We analysed data from 1590 laboratory confirmed hospitalised patients from 575 hospitals in 31 provinces/autonomous regions/provincial municipalities across mainland China between 11 December 2019 and 31 January 2020. We analysed the composite end-points, which consisted of admission to an intensive care unit, invasive ventilation or death. The risk of reaching the composite end-points was compared according to the presence and number of comorbidities. RESULTS The mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424–5.048)), diabetes (1.59 (1.03–2.45)), hypertension (1.58 (1.07–2.32)) and malignancy (3.50 (1.60–7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16–2.77) among patients with at least one comorbidity and 2.59 (1.61–4.17) among patients with two or more comorbidities. CONCLUSION Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.
1000 Sacherschließung
gnd 1206347392 COVID-19
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/R3VhbiwgV2VpLWppZQ==|https://frl.publisso.de/adhoc/uri/TGlhbmcsIFdlbi1odWE=|https://frl.publisso.de/adhoc/uri/WmhhbywgWWk=|https://frl.publisso.de/adhoc/uri/TGlhbmcsIEhlbmctcnVp|https://frl.publisso.de/adhoc/uri/Q2hlbiwgWmktc2hlbmc=|https://frl.publisso.de/adhoc/uri/TGksIFlpLW1pbg==|https://frl.publisso.de/adhoc/uri/TGl1LCBYaWFvLXFpbmc=|https://frl.publisso.de/adhoc/uri/Q2hlbiwgUnUtY2hvbmc=|https://frl.publisso.de/adhoc/uri/VGFuZywgQ2h1bi1saQ==|https://frl.publisso.de/adhoc/uri/V2FuZywgVGFv|https://frl.publisso.de/adhoc/uri/T3UsIENodW4tcXVhbg==|https://frl.publisso.de/adhoc/uri/TGksIExp|https://frl.publisso.de/adhoc/uri/Q2hlbiwgUGluZy15YW4=|https://frl.publisso.de/adhoc/uri/U2FuZywgTGluZw==|https://frl.publisso.de/adhoc/uri/V2FuZywgV2Vp|https://frl.publisso.de/adhoc/uri/TGksIEppYW4tZnU=|https://frl.publisso.de/adhoc/uri/TGksIENhaS1jaGVu|https://frl.publisso.de/adhoc/uri/T3UsIExpLW1pbg==|https://frl.publisso.de/adhoc/uri/Q2hlbmcsIEJv|https://frl.publisso.de/adhoc/uri/WGlvbmcsIFNoYW4=|https://frl.publisso.de/adhoc/uri/TmksIFpoZW5nLXlp|https://frl.publisso.de/adhoc/uri/WGlhbmcsIEppZQ==|https://frl.publisso.de/adhoc/uri/SHUsIFl1|https://frl.publisso.de/adhoc/uri/TGl1LCBMZWk=|https://frl.publisso.de/adhoc/uri/U2hhbiwgSG9uZw==|https://frl.publisso.de/adhoc/uri/TGVpLCBDaHVuLWxpYW5n|https://frl.publisso.de/adhoc/uri/UGVuZywgWWkteGlhbmc=|https://frl.publisso.de/adhoc/uri/V2VpLCBMaQ==|https://frl.publisso.de/adhoc/uri/TGl1LCBZb25n|https://frl.publisso.de/adhoc/uri/SHUsIFlhLWh1YQ==|https://frl.publisso.de/adhoc/uri/UGVuZywgUGVuZw==|https://frl.publisso.de/adhoc/uri/V2FuZywgSmlhbi1taW5n|https://frl.publisso.de/adhoc/uri/TGl1LCBKaS15YW5n|https://frl.publisso.de/adhoc/uri/Q2hlbiwgWmhvbmc=|https://frl.publisso.de/adhoc/uri/TGksIEdhbmc=|https://frl.publisso.de/adhoc/uri/WmhlbmcsIFpoaS1qaWFu|https://frl.publisso.de/adhoc/uri/UWl1LCBTaGFvLXFpbg==|https://frl.publisso.de/adhoc/uri/THVvLCBKaWU=|https://frl.publisso.de/adhoc/uri/WWUsIENoYW5nLWppYW5n|https://frl.publisso.de/adhoc/uri/Wmh1LCBTaGFvLXlvbmc=|https://frl.publisso.de/adhoc/uri/Q2hlbmcsIExpbi1saW5n|https://frl.publisso.de/adhoc/uri/WWUsIEZlbmc=|https://frl.publisso.de/adhoc/uri/TGksIFNoaS15dWU=|https://frl.publisso.de/adhoc/uri/WmhlbmcsIEppbi1waW5n|https://frl.publisso.de/adhoc/uri/WmhhbmcsIE51by1mdQ==|https://frl.publisso.de/adhoc/uri/WmhvbmcsIE5hbi1zaGFu|https://frl.publisso.de/adhoc/uri/SGUsIEppYW4teGluZw==
1000 Label
1000 Förderer
  1. Guangdong Science and Technology Department |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Guangdong Science and Technology Department |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6420927.rdf
1000 Erstellt am 2020-05-15T10:31:01.748+0200
1000 Erstellt von 21
1000 beschreibt frl:6420927
1000 Bearbeitet von 21
1000 Zuletzt bearbeitet 2020-05-15T10:32:06.703+0200
1000 Objekt bearb. Fri May 15 10:31:48 CEST 2020
1000 Vgl. frl:6420927
1000 Oai Id
  1. oai:frl.publisso.de:frl:6420927 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source